Annovis Bio (ANVS) Competitors $2.66 -0.15 (-5.41%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$2.70 +0.04 (+1.58%) As of 07/18/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS vs. ALXO, CYBN, TIL, PBYI, VYGR, TLSA, IMAB, LFVN, ENTA, and IPHAShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include ALX Oncology (ALXO), Cybin (CYBN), Instil Bio (TIL), Puma Biotechnology (PBYI), Voyager Therapeutics (VYGR), Tiziana Life Sciences (TLSA), I-Mab (IMAB), Lifevantage (LFVN), Enanta Pharmaceuticals (ENTA), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Its Competitors ALX Oncology Cybin Instil Bio Puma Biotechnology Voyager Therapeutics Tiziana Life Sciences I-Mab Lifevantage Enanta Pharmaceuticals Innate Pharma ALX Oncology (NASDAQ:ALXO) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership. Which has more risk and volatility, ALXO or ANVS? ALX Oncology has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Do analysts prefer ALXO or ANVS? ALX Oncology currently has a consensus target price of $3.30, indicating a potential upside of 551.40%. Annovis Bio has a consensus target price of $18.00, indicating a potential upside of 577.20%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts plainly believe Annovis Bio is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in ALXO or ANVS? 98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable earnings and valuation, ALXO or ANVS? Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$134.85M-$2.47-0.21Annovis BioN/AN/A-$24.59M-$2.16-1.23 Is ALXO or ANVS more profitable? ALX Oncology's return on equity of -104.43% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -104.43% -77.74% Annovis Bio N/A -300.56%-193.50% Does the media prefer ALXO or ANVS? In the previous week, ALX Oncology had 1 more articles in the media than Annovis Bio. MarketBeat recorded 1 mentions for ALX Oncology and 0 mentions for Annovis Bio. ALX Oncology's average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score. Company Overall Sentiment ALX Oncology Neutral Annovis Bio Neutral SummaryALX Oncology beats Annovis Bio on 7 of the 13 factors compared between the two stocks. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$54.76M$2.93B$5.56B$20.81BDividend YieldN/A2.44%3.75%3.65%P/E Ratio-1.2319.8828.2227.58Price / SalesN/A307.21436.7558.70Price / CashN/A42.5936.1622.29Price / Book3.977.678.114.66Net Income-$24.59M-$55.28M$3.25B$995.72M7 Day Performance-2.28%4.87%1.64%-0.30%1 Month Performance-1.19%11.73%7.28%4.90%1 Year Performance-76.39%3.72%33.14%11.14% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio1.6139 of 5 stars$2.66-5.4%$18.00+577.2%-76.7%$54.76MN/A-1.233ALXOALX Oncology3.169 of 5 stars$0.44-3.5%$3.30+643.2%-92.3%$24.57MN/A-0.1840Gap DownCYBNCybin3.0944 of 5 stars$7.87-0.9%$86.00+992.8%N/A$181.20MN/A-1.8050News CoverageTILInstil Bio2.424 of 5 stars$23.64-14.0%$119.00+403.4%+106.8%$180.37MN/A-1.97410High Trading VolumePBYIPuma Biotechnology4.2604 of 5 stars$3.54-1.1%$7.00+97.7%-8.1%$177.68M$230.50M4.60200Positive NewsVYGRVoyager Therapeutics3.9769 of 5 stars$3.04-5.0%$13.39+340.5%-61.6%$177.08M$80M-2.08100News CoverageTLSATiziana Life Sciences0.8131 of 5 stars$1.53+1.3%N/A+82.4%$176.44MN/A0.008IMABI-Mab2.91 of 5 stars$2.09-2.8%$6.00+187.1%+41.9%$175.57M$3.89M0.00380News CoverageGap DownLFVNLifevantage4.3121 of 5 stars$13.59-0.9%$30.50+124.4%+98.3%$172.71M$200.16M19.70260News CoveragePositive NewsENTAEnanta Pharmaceuticals3.493 of 5 stars$7.65-3.0%$18.00+135.3%-48.7%$168.66M$67.64M-1.69160IPHAInnate Pharma1.8704 of 5 stars$1.79-1.6%$11.00+514.5%-11.1%$167.76M$21.77M0.00220News CoveragePositive News Related Companies and Tools Related Companies ALX Oncology Competitors Cybin Competitors Instil Bio Competitors Puma Biotechnology Competitors Voyager Therapeutics Competitors Tiziana Life Sciences Competitors I-Mab Competitors Lifevantage Competitors Enanta Pharmaceuticals Competitors Innate Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANVS) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.